All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Checkpoint inhibitors, such as monoclonal antibodies that specifically block the action of programmed cell death protein 1 (PD-1) or its ligand, PD-L1, are very promising immunotherapy tools that can evoke strong anti-tumor immune responses. At present, checkpoint inhibitors are being tested in the pre-clinical and clinical trial setting for their efficacy in treating multiple myeloma (MM).
In this study, Camille Guillerey and Heidi Harjunpää, both from the School of Medicine, University of Queensland, Herston, Australia, and collaborators, investigated the potential of TIGIT (T cell immunoglobulin and ITIM domains), an inhibitory lymphocyte receptor, as a potential target for checkpoint inhibition in MM. The study was published in the journal Blood in July 2018.
This study supports TIGIT as an important molecule in the inhibitory checkpoint pathway in MM both in pre-clinical MM models as well as in CD8+ T cells from MM patients. This provides the basis for further investigating the use of anti-TIGIT antibodies as checkpoint inhibitors for MM.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox